Sinomune Pharmaceutical key facts
as of Oct 2026- Developer and manufacturer of pharmaceutical drugs with clinical value intended to specialize in the area of dermatology and nephrology.
- Sinomune Pharmaceutical is valued at approximately $300.5M as of Oct 2026 (last reported valuation).
- It has raised $64.4M; the latest was PE Growth/Expansion ($42.5M) in Dec 2025.
- Notable investors include Jolmo Investment, Wuxi Capital, Sinovation Ventures, Cathay Capital, Wuxi Capital Group — 8 tracked in total.
- Status: Privately Held (backing).
Sinomune Pharmaceutical's last reported valuation, Aug 2021. Nothing priced has surfaced since.
- ·Watch Sinomune Pharmaceutical: the Monday email on marks, rounds and moves
Sinomune Pharmaceutical funding rounds
No funding rounds for Sinomune Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Sinomune Pharmaceutical valuation
Sinomune Pharmaceutical's last reported valuation was $300 million in Aug 2021. No priced round, secondary trade or fund mark has surfaced since.
Sinomune Pharmaceutical investors
8 investors are on record for Sinomune Pharmaceutical, including Jolmo Investment, Wuxi Capital, Sinovation Ventures and Cathay Capital.
About Sinomune Pharmaceutical
Developer and manufacturer of pharmaceutical drugs with clinical value intended to specialize in the area of dermatology and nephrology. The company has a provincial engineering technology research center that develops products that are competitive in topical medications and tripterygium wilfordii fields, providing customers with skin topical medicine and tripterygium genus medicine.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 1999
- Employees
- 699
- Website
- sinomunepharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.